Zhao Yizhou, Moran Kathryn, Yewondwossen Mammo, Allan James, Clarke Scott, Rajaraman Murali, Wilke Derek, Joseph Paul, Robar James L
Department of Radiation Oncology, Dalhousie University, Queen Elizabeth II Health Sciences Centre, 5820 University Avenue, Halifax, Nova Scotia B3H 2Y9, Canada.
Department of Radiation Oncology, Dalhousie University, Queen Elizabeth II Health Sciences Centre, 5820 University Avenue, Halifax, Nova Scotia B3H 2Y9, Canada.
Med Dosim. 2017;42(2):150-155. doi: 10.1016/j.meddos.2017.03.001. Epub 2017 May 8.
Three-dimensional (3D) printing is suitable for the fabrication of complex radiotherapy bolus. Although investigated from dosimetric and feasibility standpoints, there are few reports to date of its use for actual patient treatment. This study illustrates the versatile applications of 3D printing in clinical radiation oncology through a selection of patient cases, namely, to create bolus for photon and modulated electron radiotherapy (MERT), as well as applicators for surface high-dose rate (HDR) brachytherapy. Photon boluses were 3D-printed to treat a recurrent squamous cell carcinoma (SCC) of the nasal septum and a basal cell carcinoma (BCC) of the posterior pinna. For a patient with a mycosis fungoides involving the upper face, a 3D-printed MERT bolus was used. To treat an SCC of the nose, a 3D-printed applicator for surface brachytherapy was made. The structures' fit to the anatomy and the radiotherapy treatment plans were assessed. Based on the treatment planning computed tomography (CT), the size of the largest air gap at the interface of the 3D-printed structure was 3 mm for the SCC of the nasal septum, 3 mm for the BCC of the pinna, 2 mm for the mycosis fungoides of the face, and 2 mm for the SCC of the nose. Acceptable treatment plans were obtained for the SCC of the nasal septum (95% isodose to 99.8% of planning target volume [PTV]), the BCC of the pinna (95% isodose to 97.7% of PTV), and the mycosis fungoides of the face (90% isodose to 92.5% of PTV). For the latter, compared with a plan with a uniform thickness bolus, the one featuring the MERT bolus achieved relative sparing of all the organs at risk (OARs) distal to the target volume, while maintaining similar target volume coverage. The surface brachytherapy plan for the SCC of the nose had adequate coverage (95% isodose to 95.6% of clinical target volume [CTV]), but a relatively high dose to the left eye, owing to its proximity to the tumor. 3D printing can be implemented effectively in the clinical setting to create highly conformal bolus for photon and MERT, as well as applicators for surface brachytherapy.
三维(3D)打印适用于制作复杂的放射治疗填充物。尽管已从剂量学和可行性角度进行了研究,但迄今为止,关于其用于实际患者治疗的报道很少。本研究通过一系列患者病例展示了3D打印在临床放射肿瘤学中的多种应用,即制作光子和调制电子放疗(MERT)的填充物以及表面高剂量率(HDR)近距离放射治疗的施源器。3D打印光子填充物用于治疗鼻中隔复发性鳞状细胞癌(SCC)和耳廓后部基底细胞癌(BCC)。对于一名累及上脸的蕈样肉芽肿患者,使用了3D打印的MERT填充物。为治疗鼻部SCC,制作了3D打印的表面近距离放射治疗施源器。评估了这些结构与解剖结构的贴合度以及放射治疗计划。根据治疗计划计算机断层扫描(CT),3D打印结构界面处最大气隙的尺寸,鼻中隔SCC为3毫米,耳廓BCC为3毫米,面部蕈样肉芽肿为2毫米,鼻部SCC为2毫米。对于鼻中隔SCC(95%等剂量线覆盖计划靶体积[PTV]的99.8%)、耳廓BCC(95%等剂量线覆盖PTV的97.7%)和面部蕈样肉芽肿(90%等剂量线覆盖PTV的92.5%),均获得了可接受的治疗计划。对于后者,与使用均匀厚度填充物的计划相比,采用MERT填充物的计划在保持相似靶体积覆盖的同时,实现了靶体积远端所有危及器官(OAR)的相对 sparing。鼻部SCC的表面近距离放射治疗计划有足够的覆盖范围(95%等剂量线覆盖临床靶体积[CTV]的95.6%),但由于左眼靠近肿瘤,对其剂量相对较高。3D打印可在临床环境中有效实施,以制作用于光子和MERT的高度适形填充物以及表面近距离放射治疗的施源器。